Benuvia Therapeutic's synthetic cannabidiol oral solution Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Location

Primary Industry

Biotechnology

About

Based in the US, Benuvia Therapeutic's synthetic cannabidiol oral solution operates as a developer of cannabis-based drugs that offers pharmaceutical companies oral medicines intended for patients with endocrine and metabolic orphan diseases such as Prader-Willi syndrome. The team works with pharmaceutical companies, by offering a synthetic cannabidiol oral medication. The RAD011 is a synthetic cannabidiol oral medication that helps patients with orphan endocrine diseases. The study focuses on the development of medication for Prader-Willi syndrome. The team's revenue is generated by offering this oral medication. Pharmaceutical companies will contact the parent company, specifically, the team of researchers under synthetic cannabidiol oral solution study, which focuses on Prader-Willi syndrome. In 2021, the team was acquired by Radius Health, Inc., which operates as a biopharmaceutical company that develops drug therapies for patients with osteoporosis and breast cancer. The parent company will use the fund for product research and development.

Current Investors

Radius Health, Inc.

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Pharmaceutical Research & Development

Website

www.benuvia.com

Company Stage

Add-on

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.